Rare Cancers Act 2026

A vote to support means

• —Patients with rare cancers face delayed diagnoses because symptoms are unfamiliar to GPs and generalist consultants; this bill funds specialist diagnostic centres that can identify these conditions faster, improving survival rates
• —Rare cancers are commercially unviable for pharmaceutical companies, leaving patients without treatment options; the bill creates research funding streams and incentives to develop therapies for these neglected diseases
• —A centralised patient registry enables doctors to share treatment outcomes and best practices across the NHS, meaning patients benefit from collective learning rather than isolated hospital experiences
• —Dedicated funding removes competition between rare and common cancers for limited NHS resources, ensuring this patient group isn't systematically disadvantaged

A vote to oppose means

• —The bill requires significant NHS budget reallocation; funding specialist rare cancer centres may reduce resources for common cancers that affect far more patients, potentially impacting treatment times for breast, lung, or bowel cancer patients
• —Creating multiple specialist centres risks fragmenting care and creating travel burdens for patients in rural areas, who may need to travel hundreds of miles for treatment at designated hubs
• —Mandatory diagnostic targets (12 weeks) could pressure trusts to provide preliminary diagnoses without confirmed pathology, leading to patient anxiety and potential misdiagnosis
• —The patient registry raises privacy concerns; centralised collection of genetic and medical data on rare cancer patients creates a vulnerable dataset that could be misused if security is compromised